These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
695 related articles for article (PubMed ID: 28889366)
21. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [ Berliner C; Tienken M; Frenzel T; Kobayashi Y; Helberg A; Kirchner U; Klutmann S; Beyersdorff D; Budäus L; Wester HJ; Mester J; Bannas P Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):670-677. PubMed ID: 27896369 [TBL] [Abstract][Full Text] [Related]
22. Preliminary results on response assessment using Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010 [TBL] [Abstract][Full Text] [Related]
23. Clinical performance of Kranzbühler B; Nagel H; Becker AS; Müller J; Huellner M; Stolzmann P; Muehlematter U; Guckenberger M; Kaufmann PA; Eberli D; Burger IA Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):20-30. PubMed ID: 29032394 [TBL] [Abstract][Full Text] [Related]
24. PET/CT With Giovacchini G; Giovannini E; Riondato M; Ciarmiello A Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673 [TBL] [Abstract][Full Text] [Related]
27. Wang R; Shen G; Yang R; Ma X; Tian R Eur J Radiol; 2020 Sep; 130():109131. PubMed ID: 32622250 [TBL] [Abstract][Full Text] [Related]
28. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes. Barbaud M; Frindel M; Ferrer L; Le Thiec M; Rusu D; Rauscher A; Maucherat B; Baumgartner P; Fleury V; Colombié M; Thierry-Morel A; Kraeber-Bodéré F; Campion L; Rousseau C Prostate; 2019 Apr; 79(5):454-461. PubMed ID: 30549066 [TBL] [Abstract][Full Text] [Related]
30. 68Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study. Lengana T; van de Wiele C; Lawal I; Maes A; Ebenhan T; Boshomane T; Zeevaart JR; Ankrah A; Mokgoro N; Vorster M; Sathekge M Nucl Med Commun; 2018 Feb; 39(2):179-185. PubMed ID: 29257006 [TBL] [Abstract][Full Text] [Related]
37. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132 [TBL] [Abstract][Full Text] [Related]
38. Diagnostic Performance of 68Ga-PSMA-11 Positron-emission-tomography/Computed-tomography in a Large Cohort of Patients with Biochemical Recurrence of Prostate Carcinoma. Hoffmann MA; Buchholz HG; Wieler HJ; Müller-Hübenthal J; Trampert L; Richardsen I; Schreckenberger M Health Phys; 2020 Jul; 119(1):141-147. PubMed ID: 32301863 [TBL] [Abstract][Full Text] [Related]
39. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446 [TBL] [Abstract][Full Text] [Related]
40. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]